Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAVE-AA-PEDS
2022-502700-78-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in alopecia areata comparing Baricitinib with Placebo (2 arms). Primary endpoint: Percentage of participants achieving an absolute Severity of Alopecia Tool (SALT) score of 20 or less. Planned start Sep 2023; status: authorised.
02
Drugs
baricitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on 2022-502700-78-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502700-78-00.